Compare abrdn Income Credit Strategies Fund (ACP) vs CVS Health Corp (CVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs CVS Health Corp — how do they compare? abrdn Income Credit Strategies Fund trades at $5.21 (market cap $656.21M), while CVS Health Corp trades at $105 (market cap $133.12B). The key difference: CVS Health Corp is far larger — about 202.9× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (17.78%). Which is the better fit depends on your goals.
| ACP | CVS | |
|---|---|---|
Market Cap | $656.21M | $133.12B |
Sector | Financials | Health |
52-Week High | $5.98 | $104.81 |
52-Week Low | $5.01 | $58.75 |
Dividend Yield | 17.78% | 2.55% |
Enterprise Value | — | $199.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
CVS Health trades at $104.33, down slightly on the day, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates, including a recent Q1 2026 beat, and benefits from positive sentiment around strategic initiatives like GLP-1 drug access. Revenue growth remains solid, though net margins are thin. The current price sits just below the consensus price target of $106.86.
The outlook for CVS is positive, driven by earnings momentum and strategic positioning in healthcare services. Key opportunities include margin expansion potential and market share gains. Risks involve intense competition, regulatory pressures on healthcare pricing, and the company's significant debt load, which requires careful management of cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
